At a Glance
| Ephedrine | 2-Aminoindane | |
|---|---|---|
| Class | Stimulants | Stimulants |
| Common Dose (oral) | 20–30 mg | 10–20 mg |
| Total Duration | 0.3–1.5 hrs | 0.2–0.5 hrs |
| Routes | oral | oral |
| Effects | 28 documented | 27 documented |
Ephedrine, a Stimulants, and 2-Aminoindane, a Stimulants, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Both are classified as Stimulantss, meaning they share a common pharmacological foundation. They share 14 documented effects in common, with 14 effects unique to Ephedrine and 13 unique to 2-Aminoindane. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Ephedrine | 2-Aminoindane | |
|---|---|---|
| Class | Stimulants | Stimulants |
| Common Dose (oral) | 20–30 mg | 10–20 mg |
| Total Duration | 0.3–1.5 hrs | 0.2–0.5 hrs |
| Routes | oral | oral |
| Effects | 28 documented | 27 documented |
| Interaction |
| Caution |
| Level | Ephedrine | 2-Aminoindane |
|---|---|---|
| Threshold | 5 mg | 3 mg |
| Light | 10–20 mg | 5–10 mg |
| Common | 20–30 mg | 10–20 mg |
| Strong | 30–50 mg | 20–40 mg |
| Heavy | 50 mg | 40 mg |
Ephedrine
2-Aminoindane
Increased cardiovascular strain and neurotoxicity risk